Axogen Valuation Multiples

Axogen Overview

About Axogen

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.

Founded

1977

HQ

Employees

622

Website

axogeninc.com

Sectors

Medical DevicesDeepTechHealthTechBioTech

Financials (LTM)

Revenue: $237M

EBITDA: $28M

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Axogen Financials

Axogen reported last 12-month revenue of $237M and EBITDA of $28M.

In the same LTM period, Axogen generated $177M in gross profit, $28M in EBITDA, and had net loss of ($17M).

Axogen P&L

In the most recent fiscal year, Axogen reported revenue of $225M and EBITDA of $26M.

Axogen expects next 12-month revenue of XXX and NTM EBITDA of XXX

Axogen Stock Performance

Axogen has current market cap of $2B, and enterprise value of $2B.

Axogen's stock price is $38.48.

Axogen Valuation Multiples

Axogen trades at 8.5x EV/Revenue multiple, and 72.1x EV/EBITDA.

Axogen Financial Valuation Multiples

As of April 20, 2026, Axogen has market cap of $2B and EV of $2B.

Equity research analysts estimate Axogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Axogen has a P/E ratio of (119.4x).

Axogen Margins & Growth Rates

Axogen's revenue in the last 12 month grew by 18%.

Axogen's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.

Axogen's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Axogen's rule of X is 58% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Axogen Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Axogen M&A Activity

Axogen acquired XXX companies to date.

Last acquisition by Axogen was on XXXXXXXX, XXXXX. Axogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Axogen Investment Activity

Axogen invested in XXX companies to date.

Axogen made its latest investment on XXXXXXXX, XXXXX. Axogen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).